NCT01455922撤回3 期
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Intarcia Therapeutics1 个研究点 分布在 1 个国家开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Change in HbA1c
研究概览
简要总结
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HbA1c between 7.5% - 10.5%
- •on metformin monotherapy
- •BMI between 25 & 45 kg/m2
排除标准
- •On thiazolidinedione, sulfonylurea, DPP-4, alpha glucosidase inhibitor, meglitinides or insulin within last 3 months
- •history of pancreatitis
研究组 & 干预措施
ITCA 650 60 mcg/day
Experimental
干预措施: ITCA 650 (Drug)
glimepiride
Active Comparator
干预措施: glimepiride (Drug)
结局指标
主要结局
Change in HbA1c
时间窗: 52 weeks
52-week Treatment Period followed by 52-week Extension Period
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
3 期
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesType 2 DiabetesNCT01455883Intarcia Therapeutics
撤回
3 期
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesType 2 DiabetesNCT01455909Intarcia Therapeutics
已完成
3 期
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesType 2 DiabetesNCT01455870Intarcia Therapeutics535
终止
3 期
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01834274Takeda96
已完成
3 期
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately ControlledType 2 Diabetes MellitusNCT01699932Sanofi167